Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 triM: First- line therapy with FOLFIRI plus Cetuximab or Bevacizumab in patients with KRAS wild- type tumors in metastatic colorectal cancer

查看全文 作　　者：Modest DP; Stintzing S; van Weikersthal LF; 出　　处：《J Clin Oncol》索引2015年第33卷第32期,共0页